The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

As Novartis moves ahead plans to expand Pluvicto's use based on the PSMAddition trial, experts urge for greater use of ...

RemeGen's disitamab vedotin with Junshi Pharma's Loqtorzi beat standard chemotherapy in first-line HER2-expressing metastatic urothelial cancer.

NEW YORK – Taysha Gene Therapies has regained full rights to its lead program, TSHA-102, for Rett syndrome after an option agreement with Astellas expired.

In a Phase III trial, sacituzumab tirumotecan outperformed chemo in previously treated EGFR-mutant NSCLC patients, results presented at the ESMO Congress show.

The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.